Phil Reason, the chief executive of Instem (), provides an insight into the AIM-listed business, which supplies IT applications to companies working on the early phases of developing drugs and chemicals.
It has a robust customer base, with over 400 clients to date serviced by its offices in the US, UK, China and India.
Reason explains how the firm is focusing on market share, client retention, increasing recurring revenue and margin enhancement.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Instem PLC named herein, including the promotion by the Company of Instem PLC in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HERE